Biological Treatment for Rheumatic Diseases

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: 25 August 2024 | Viewed by 614

Special Issue Editor


E-Mail Website
Guest Editor
Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland
Interests: connective tissue diseases; pathology of the extracellular matrix; growth factors; systemic sclerosis; juvenile idiopathic arthritis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The implementation of biological drugs into the treatment of rheumatic diseases has opened new possibilities in the management of diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. The development of "targeted" therapies that are more effective at inhibiting bone and joint destruction has significantly improved the life quality of patients. Some of these therapies lead to both the inhibition of locally ongoing lesions in the vicinity of the joints and the inhibition of generalized disease processes. However, not all patients respond positively to biological therapy. Moreover, the long-term use of biological drugs may be associated with a decrease in their efficacy as well as the occurrence of side effects related to the potential immunogenicity of these medicines. This is because biological drugs can induce an immune response and the synthesis of anti-drug antibodies (ADA, anti-drug antibodies). Therefore, it is important to understand the detailed mechanisms through which metabolic changes occur when using biological drugs. In this Special Issue, our goal is to bring together the results of expert research in this field, allowing us to better understand the effects of biological drugs on metabolic processes occurring in the body and provide an opportunity for medicines to be used more effectively in treating rheumatic diseases.

Dr. Kornelia Kuźnik-Trocha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biological drugs
  • new treatment strategies
  • antirheumatic agents
  • arthritis
  • rheumatic diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3818 KiB  
Article
Plasma Sclerostin Levels in Rheumatoid Arthritis Women on TNF-α Inhibitor Therapy
by Anna Szeremeta, Agnieszka Jura-Półtorak, Aleksandra Zoń-Giebel, Krystyna Olczyk and Katarzyna Komosińska-Vassev
Pharmaceuticals 2024, 17(6), 666; https://0-doi-org.brum.beds.ac.uk/10.3390/ph17060666 - 22 May 2024
Viewed by 455
Abstract
Rheumatoid arthritis (RA) is associated with significant systemic and local bone loss. The aim of this study was to assess whether or not 15-month tumor necrosis factor α inhibitor (TNFαI) therapy in combination with methotrexate (MTX) affects circulating levels of sclerostin (SOST) in [...] Read more.
Rheumatoid arthritis (RA) is associated with significant systemic and local bone loss. The aim of this study was to assess whether or not 15-month tumor necrosis factor α inhibitor (TNFαI) therapy in combination with methotrexate (MTX) affects circulating levels of sclerostin (SOST) in female RA patients. Plasma levels of SOST were measured using immunoassays kits. Baseline SOST levels showed no significant differences between RA patients and control participants. Postmenopausal women with RA tended to have higher sclerostin levels than premenopausal woman with RA. After 15 months of treatment with TNFαI, plasma levels of SOST were decreased. Before starting biological therapy, circulating levels of SOST significantly correlated with the patient’s age (p < 0.05) and the marker of inflammation, such as ESR (p < 0.05). Multivariate regression analysis showed that age was the only significant predictor for baseline SOST levels in women with RA (β = 0.008, p = 0.028, R2 model = 0.293). Moreover, a positive correlation between SOST levels and the 28 joint disease activity score value based on the erythrocyte sedimentation rate (DAS28-ESR) was found at baseline (p < 0.05), as well as after 15 months of biological therapy (p < 0.05). Thus, plasma SOST levels may be helpful for monitoring the efficacy of TNFαI treatment in RA patients. According to our results, TNFαI, in combination with MTX, has a beneficial effect on bone turnover with a significant reduction in bone metabolism marker SOST. Full article
(This article belongs to the Special Issue Biological Treatment for Rheumatic Diseases)
Show Figures

Figure 1

Back to TopTop